/주식/BMEA
BMEA

BMEA

USD

Biomea Fusion Inc. Common Stock

$2.610+0.140 (5.668%)

실시간 가격

Healthcare
생명공학
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$2.470

고가

$2.650

저가

$2.435

거래량

2.30M

기업 기본 정보

시가총액

98.1M

산업

생명공학

국가

United States

거래 통계

평균 거래량

1.91M

거래소

NMS

통화

USD

52주 범위

저가 $1.291현재가 $2.610고가 $13.07

관련 뉴스

GlobeNewswire

Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities

PALM BEACH, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The Retinal and Fundis Camera market has shown growth in the recent years and is expected to continue for years to come. Fundus

더 보기
Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities
Analyst Upgrades

Piper Sandler Assumes Biomea Fusion at Overweight, Announces Price Target of $7

Piper Sandler analyst Edward Tenthoff assumes Biomea Fusion with a Overweight rating and announces Price Target of $7.

더 보기
Piper Sandler Assumes Biomea Fusion at Overweight, Announces Price Target of $7
Analyst Upgrades

D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $16 Price Target

D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion with a Buy and maintains $16 price target.

더 보기
D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $16 Price Target
GlobeNewswire

Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced that preliminary clinical data from the

더 보기
Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia